The NIH/NLM MedlinePlus monograph for pramlintide injection opens by stating the drug has been discontinued in the U.S. market and that the monograph is no longer updated as a result. The patient-facing entry still documents pramlintide's use with mealtime insulin, hypoglycemia risk in the 3 hours post-injection, and the Symlin Pen delivery device.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.